Latest News - IQVIA
Top Corporates Hub
IQVIA
Earnings Preview: Veracyte (VCYT) Q2 Earnings Expected to Decline
23.07.2026 14:00
Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IQVIA Holdings (IQV) Reports Next Week: Wall Street Expects Earnings Growth
21.07.2026 14:00
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AI Bubble Risks Make Dividend Stocks Attractive Again
18.07.2026 13:03
Discover dividend stocks and REITs to hedge AI bubble risk, geopolitics, and inflation. Click for this survey of great income choices and my ultimate pick.
1 Cash-Producing Stock to Target This Week and 2 We Question
10.07.2026 07:43
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
IQVIA (IQV) Just Drew A New Artisan Partners Bet On AI And Resilience
09.07.2026 16:11
Artisan Partners has initiated a new position in IQVIA Holdings (NYSE:IQV), highlighting its view on the company's resilience and AI upside. The investor has publicly argued that IQVIA's exposure to AI could support the business, even as parts of the clinical research industry face concern about disruption and demand softness. IQVIA Holdings, trading at $203.79, sits at an interesting point for investors, with the stock up 10.9% over the past 30 days and 25.8% over the past year. Longer...
Is IQVIA Holdings (IQV) Resilient to AI Concerns?
08.07.2026 11:29
Artisan Partners, an investment management firm, issued its first-quarter 2026 investor letter for the “Artisan Mid Cap Value Fund”. A copy of this letter is available for download here. In Q1 2026, the portfolio underperformed the benchmark Russell Midcap Value Index as the market favored momentum-driven stocks over quality factors. Some holdings faced company-specific setbacks and […]
Why Is IQVIA (IQV) Stock Soaring Today
01.07.2026 18:33
Shares of clinical research company IQVIA (NYSE: IQV) jumped 5.8% in the afternoon session after Baird raised its price target on the stock to $249 from $230 and designated it a 'bullish Fresh Pick'.
Baird Maintains Outperform on IQVIA Holdings, Raises Price Target to $249
01.07.2026 07:02
Baird analyst Eric Coldwell maintains IQVIA Holdings (NYSE:IQV) with a Outperform and raises the price target from $230 to $249.
Does Slower Growth at IQVIA Holdings (IQV) Challenge Its Core Data‑Driven Pharma Enablement Story?
24.06.2026 02:09
In recent days, IQVIA Holdings has been in focus after commentary underscored ongoing growth challenges, with revenue increases lagging peers and constant-currency trends pointing to softer demand and pressure on market share. This underlines a tension between IQVIA’s broad role in enabling pharmaceutical development and commercialization and the current struggle to convert that position into stronger growth momentum. Next, we’ll examine how these ongoing growth challenges and softer demand...
1 Healthcare Stock with Impressive Fundamentals and 2 We Turn Down
23.06.2026 08:40
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently - over the past six months, the collective 5.2% gain for healthcare stocks has fallen short of the S&P 500’s 8.5% rise.
1 of Wall Street’s Favorite Stocks on Our Buy List and 2 We Turn Down
22.06.2026 11:31
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Morgan Stanley sees writing on wall for key drug research stocks
19.06.2026 02:03
Wall Street just split sharply on two stocks in the same industry. On Wednesday, June 17, Morgan Stanley upgraded Charles River Laboratories (CRL) to Overweight and downgraded IQVIA Holdings (IQV) to Equal-weight. The twist: IQVIA is buying lab assets that Charles River agreed to sell earlier this ...
Morgan Stanley favors Charles River Over IQVIA in CRO sector reset
17.06.2026 13:13
Investing.com -- Morgan Stanley upgraded contract research organization (CRO) provider Charles River Laboratories while downgrading IQVIA, arguing that improving biotech funding and portfolio changes create a more attractive risk-reward profile for Charles River, while longer-term uncertainty tied to artificial intelligence and pharma insourcing weighs on IQVIA.
IQVIA (IQV): Buy, Sell, or Hold Post Q1 Earnings?
17.06.2026 09:32
Over the last six months, IQVIA’s shares have sunk to $177.52, producing a disappointing 19.8% loss - a stark contrast to the S&P 500’s 12.4% gain. This might have investors contemplating their next move.
Morgan Stanley Downgrades IQVIA Holdings to Equal-Weight, Lowers Price Target to $200
17.06.2026 08:59
Morgan Stanley analyst Kallum Titchmarsh downgrades IQVIA Holdings (NYSE:IQV) from Overweight to Equal-Weight and lowers the price target from $225 to $200.
IQVIA Debt Refinance And EPS Upgrade Reshape Long Term Risk Profile
06.06.2026 10:05
IQVIA Holdings (NYSE:IQV) has announced a €950 million senior notes offering. The company intends to use the proceeds to refinance existing debt and increase financial flexibility. Management has also revised adjusted earnings per share guidance for 2026 upward. For investors watching IQVIA Holdings at a current share price of $183.45, this new financing move is a key update. The stock is up 4.0% over the past 30 days and 20.4% over the past year, although it is down 18.6% year to date and...
IQVIA (IQV) Up 3.2% Since Last Earnings Report: Can It Continue?
04.06.2026 15:30
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IQVIA Announces Pricing of Senior Notes
04.06.2026 14:51
RESEARCH TRIANGLE PARK, N.C., June 04, 2026--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the "Issuer"), priced an offering of €950,000,000 in aggregate principal amount of senior notes due 2033 (the "Notes"). The proceeds from the Notes offering will be used to refinance certain of the Issuer’s existing indebtedness and to pay fees and expenses related to the Notes offering.
Is Veeva Stock Undervalued At $170?
04.06.2026 12:38
The biggest insight hiding inside the recent Q1 FY27 earnings report from Veeva Systems (VEEV) is the stark divergence between management's artificial intelligence narrative and the structural realities of its legacy software business. While leadership dedicated significant time to detailing the launch of Veeva Falcon for agentic labor and the Ostro acquisition, the underlying financial tension centers entirely on the forced migration of its CRM customer base.